(19)
(11) EP 1 589 947 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.08.2016 Bulletin 2016/34

(45) Mention of the grant of the patent:
15.06.2016 Bulletin 2016/24

(21) Application number: 03800395.0

(22) Date of filing: 31.12.2003
(51) International Patent Classification (IPC): 
A61K 9/16(2006.01)
(86) International application number:
PCT/US2003/041703
(87) International publication number:
WO 2004/060351 (22.07.2004 Gazette 2004/30)

(54)

PHARMACEUTICAL FORMULATION WITH AN INSOLUBLE ACTIVE AGENT FOR PULMONARY ADMINISTRATION

PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND EINEN UNLÖSLICHEN WIRKSTOFF ZUR PULMONALEN VERABREICHUNG

FORMULATION PHARMACEUTIQUE AYANT UN AGENT ACTIF INSOLUBLE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: 31.12.2002 US 437210 P

(43) Date of publication of application:
02.11.2005 Bulletin 2005/44

(73) Proprietor: Novartis AG
4002 Basel (CH)

(72) Inventors:
  • TARARA, Thomas, E.
    Burlingame, CA 94010 (US)
  • WEERS, Jeffry, G.
    Belmont, CA 94002 (US)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstrasse 3
81675 München
81675 München (DE)


(56) References cited: : 
WO-A-99/16419
US-A1- 2002 017 295
 WO-A-02/067902
   
  • INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY, vol. 1, no. 7, 2000, pages 111-116, XP001182817
  • KIM J-C ET AL: "PREPARATION BY SPRAY DRYING OF AMPHOTERICIN B-PHOSPHOLIPID COMPOSITE PARTICLES AND THEIR ANTICELLULAR ACTIVITY" DRUG DELIVERY, ACADEMIC PRESS, ORLANDO, FL, US, vol. 8, no. 3, 2001, pages 143-147, XP001105573 ISSN: 1071-7544
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).